STAT May 31, 2023
The Food and Drug Administration approved a second vaccine to protect older adults against RSV on Wednesday, giving a green light to Pfizer’s Abrysvo for adults 60 and older.
Early in May the FDA approved the first ever vaccine against respiratory syncytial virus, or RSV, when it licensed GSK’s Arexvy.
“A vaccine to help prevent RSV had been an elusive public health goal for more than half a century. Today’s approval is a monumental step forward in delivering on Pfizer’s commitment to help alleviate the significant burden of RSV in higher-risk populations, which includes older adults,” Annaliesa Anderson, a Pfizer senior vice president and chief scientific officer for vaccine research and development, said in a statement.
Neither Pfizer’s vaccine nor...
Today's Sponsors
Today's Sponsor